Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Year: 2013
Type: article
Source: European Journal of Pharmacology
Institutions: Astellas Pharma (Japan), Astellas Pharma (Netherlands)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2095574383
